Advances in the treatment of schizophrenia

British Journal of Clinical Practice

Volumn 50, Issue 6, 1996, Pages 315-323

  Kuperberg, G R ^a,b   Murray, R ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

COGNITIVE THERAPY; DRUG THERAPY; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW; SCHIZOPHRENIA; TREATMENT REFUSAL;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; DRUG THERAPY; HUMANS; SCHIZOPHRENIA; TREATMENT REFUSAL;

EID: 0030228605     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (190)

1. Delay J, Deniker P, Harl JM. Utilisation en therpeutique psychiatrique d'une phenothiazine d'action centrale elective. Ann Med Psychol 1952; 110: 112-117.
2. Seeman P, Chau-Wong M, Tedesco J et al. Brain receptors for antipsychotic drugs anddopamine: direct binding assay. Proc Natl Acad Sci, USA 1975; 72: 4376-4380.
3. Seeman P, Lee T, Chau-Wong M et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719.
4. Matthysse S. Dopamine and the pharmacology of schizophrenia: the state of the evidence. J Psychiair Res 1974; 11: 107-113.
5. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246.
6. De la Chapelle A, Kari C, Nurminen M et al. Clozapine-induced agranulocytosis, a genetic and epidemiologic study. Hum Genet. 1977; 37: 183-194.
7. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992; 160 (suppl.17): 38-40.
8. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 1988; 45: 787-796.
9. Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-reisistant schizophrenic: results of a US multicenter trial. Psychopharmacology 1989; 99: 60-63.
10. Dearry A, Gingrich JA, Falardeau P et al. Molecular cloning and expression of the gene for a human Dl dopamine receptor. Nature 1990; 347:72-76.
11. Sokoloff P, Giros B, Martres MP et al. Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-151.
12. Sunahara RK, Guan HC, O'Dowd BF et al. Cloning of the gene for human dopamine D5 receptor with higher affinity for dopamine than D l. Nature 1991; 350: 614-619.
13. Van-Tol HH, Bunzow JR, Guan HC et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614.
14. Seeman P, Van Toi HH. Dopamine receptor pharmacology. Trends in Pharmacol Sci 1994; 15: 264-270.
15. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995; 346: 743-749.
16. Farde L, Nordstrom AL. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992; 160: 30-33.
17. Karbe H, Wienhard K, Harnacher K et al. Positron emission tomography with (18F) methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm, Gen Section 1991; 86: 163-173.
18. Brücke T, Roth J, Podreka I et al. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 1992; 339: 497.
19. Pilowsky LS, Costa DC, P.J. E et al. Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199-202.
20. Hoyer D, Gozlan H, Bolanos F et al. Interaction of psychotropic drugs with central 5HT3 recognition sites: fact or artifact? Eur J Pharmacol 1989; 171: 137-139.
21. Roth BL, Craigo SC, Choudhary MS et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6 and 5-hy-droxytryptamine 7 receptors. J Pharm Exp Ther 1994: 268: 1403-1410.
22. Leyscn JE. Biochemical profile of risperidone. a new antipsychotic. J Pharm E.vp Ther 1988: 247: 661-670.
23. Ereshefsky L. Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993: 38 (suppl.3): S8Ü-S88.
24. Moore NA, Calligaro DO. Wong DT et al. The pharmacology of olan/apine and other new antipsychotic agents. Cnrr Opin Invest Dnis 1993:2:2X1-293.
25. Goldstein JM. Arvanitis L. ICI 204.636 (Seroquel): A Dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Revs 1995: 1: 50-73.
26. Sanchez C, Amt J, Dragsted N el al. Ncurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991; 22: 229-250.
27. SeegerTF. Seymour PA, Schmidt AW et al. Ziprasidone (CP-88.059): A new antipsychotic with combined dopatnine and serotonin receptor antagonist activity. J Pharm Exp Tlicr 1995: 275: 1(11-113.
28. Pilowsky LS. Busatto CF. Taylor M et al. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine -a 1231 1BZM single photon emission tomography (SPET) study. Psychophurmacology 1996: (In press).
29. Sailer CF. Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol Berl 1993: 112: 285-292.
30. Hyttel J. Arnt J, Costall B et al. Pharmacological profile of the atypical neuroleptic sertindole. Clinical Nciirophurnnicol 1992: 15: 267A-268A.
31. Goldstcin JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drills 1995; 4: 291-298.
32. Köhler C, Hall H, Magnusson O et al. Biochemical pharmacology of the atypical neuroleptic reinoxipride. Act Psychiatr Scand (suppl.) 1990;358:27S-36S.
33. Debonnel G. Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J Psychiatr Neurosci 1993: 18: 157-172.
34. Graybiel AM, Besson MJ. Weber E. Neuroleptic-sensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia niera, pars compacta of the cat. J Neurosci 1989:9:326-338.
35. Mayor ML. Vyklicky L. Jr.. Sernagor E. A physiologist's view of the N-methyl-D-aspartate receptor: An allosteric ion channel with multiple regulatory sues. DruK Oev Rex 1989; 17: 263-280.
36. Javitt DC. Negative symptomotology and the PCP (phencyelidine) model of schizophrenia. J Psychiatr 1987: 9: 12-35.
37. Halbcrstadt AL. The phencyelidine-glutamate model of schi/ophrenia. Clin Neuropharmacol 1995; 18: 237-249.
38. Benlall RP. Day JC. Psychological factors and neuroleptic therapy: some neglected issues, Int Rev Psychiatr 1994:6:217-225.
39. Hoge SK. Appelbaum PS. Lawlor T et al. A prospective multicenter study of patients 'refusal of antipsychotic medical ion. Arch Gen Psychiatr 1990: 47: 949-956.
40. Van Putten T. May PR. Marder SR. Response to antipsychotic medication: The doctor's and the consumer's view. Am J Psychiatr 1984: 141: 16-19.
41. Fleischhacker WW. Meise U. Günther V el al. Compliance with antipsycholic druu treatment: influence of side effects. Acta Ps\chiatr Scand (Suppl) 1994:382: 11-15.
42. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992: 22: 787-797.
43. Van Putten T. Marder S. Behavioural Toxicity of antipsychotic drugs. J Clin Psychiatr 1987: 48: 13-19.
44. Rifkin A. Extrapyramidal side effects: A historical perspective. J Clin Psychiatr 1987;48:'3-6.
45. Delay J. Deniker P. Le trailment des psychoses par une méthode neurolyptique derive de I'hibernotherapie. In: Cossa P. Ed. Congres Medicins Alienisic et Neuruogiste de France, Paris: Maisson Editeurs Libraires de L'Académie de Medicine. 1952: 497-502.
46. Anden NE, Stock G. Effect of clozapine on thé turnover of dopamine in thé corpus striatum and in thé limbic system. J Pharm Pharmacol 1973: 25: 346-348.
47. Maidment NT, Marsden C. Acute administration of clozapine, thioridaxine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-H1AA. measured in the nucleus accumbens and striatum of the rat using in vivo voltammetrv. Neitropharmiicoltigv 1987; 26: 187-193.
48. Roffman M. Bernard PS. Dawson KM ct al. The effects of haloperidol and clozapine on circling induced by electrical stimulation of the sub-stanlia nigra in the venlromcdial tegnienlum. Neuropharmacology 1978: 17:943-946.
49. Ljunberg T. Ungerstedt U. Classil'icalion of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Pswliopharmacology 1978:56: 239-247.
50. Chiodo LA, Bunney BS. Typcial and atypical neuroleptics- Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983: 3: 1607-1619.
51. Bunney BS. Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci 1984: 7: 212-215.
52. Hand TH, Hu XT. Wang RY. Differential effects of acute clo/apine and halperidol on the activity of ventral tegmental (AlO)andnigrostriatal (A9) dopamine neurons. Brain Rex 1987; 415: 257-269.
53. Stockten ME. Rasmu.ssen K. A comparison of olan/apine and clozapine effects on dopamine neuronal activity. Sucietv fur Neuroscience Abstracts 1993: 19: 383.
54. Skarsfeldt T. Perregaard J. Sertindole, a new neuroleptic w ith extreme selectivity on Aid versus A9 dopamine neurons in the rat. Ear J Pluir mucol 1990: 182:613-614.
55. Snyder SH. The dopamine connection. Nature 1990: 347: 121-122.
56. Farde L. Nordstrom AL, Wiesel FA et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch (Gen Psychiatr 1992: 49: 538-544.
57. Nordstrom AL. Farde L. Weisel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a doubleblind PET study of schizophrenic patients. Bial Psychiatry 1993: 33: 227-235.
58. Pilowskv LS. Costa DC. Ell PJ et al. Antipsychotic medication, D2 dopamine receptor blockade and clinical response - a 12311BZM SPET (single photon emission tomography) study. Psychol Med 1993: 23: 791 -799.
59. Wolkin A. Barouche F. Wolf APet al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J Psych 1989; 146:905-908.
60. Busatto GF. Pilowsky LS, Costa DC et al. Dopamine D2 receptor blockade in vivo which the novel antipsychotics risperidonc and remoxipride -an 1231-IBZ.M single photon emission tomography (SPET) study. Psychopharmacology Berl. 1995: 117:55-61.
61. Schwartz JC. Levesque D. Martres MPet al. Dopamine D3 Receptor: Basic and Clinical Aspects. Clin Neuropharmacol 1993: 16: 295-314.
62. Surmeier DJ. Reiner A. Levine MS et al. Are neostriatal dopamine receptors co-localized? Trends Neurosci 1993: 16:299-305.
63. Clark D. White FJ. Dl dopamine receptor -the search for function: critical evaluation of the D1-D2 dopamine receptor classification and its functional implications. Synapse 1987: 1: 347-388.
64. SnyderSH. GreenbergD. Yamamura HI. Antischizophrenic drugs and brain chlolinergic receptors. Arch Gen Psychialr 1974; 31: 58-61.
65. Lane RF. Blaha CD. Rivet JM. Selective inhibition of mesolimbic dopamine release following chronic administration ofclozapine: involvement of al-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 1988; 460: 398-401.
66. I'gedo L. Grenhot'f J. Svenson TH. Ritanserin. a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotoner gic inhibition. Psychopharmacology 1989: 98: 45-50.
67. Saller CF. Czupryna MJ. Salama Al. 5-HT2 receptor blockade by ICI 169.369 and other 5-HT2 antagonists modulates the effects of D2 dopamine receptor blockade. J Pharmacol Exp Ther 1990: 253: 11621170.
68. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus halopendol. Br J Psychiatr 1995: 1995:712-726.
69. Chouinard G. Jones B. Remington G et al. A Canadian multicentrc placebo-controlled study of fixed doses of risperidone and halopendol in the treatment of chronic schizophrénie patinets. J Clin Psychopharmacol 1993: 13: 25-40.
70. Moore NA. Tye NC. Axton MS et al. The behavioural pharmacology of olanzpine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 1992:262: 545-551.'
71. Targum S. Zhoroviski J. Henry M et al. Efficacy and safety of sertindole in two double-blind, placebo controlled trials of schizophrenic patients (Abstract). Eur Neuropsychopharmacol 1995; 5: 348-349.
72. Bebhington PE. The content and context of compliance, Int Clin Psychopharmacol 1995: 9: 41-50.
73. Sellwood W, Tarricr N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatr Epidemiol 1994:29: 172-177.
74. Seltzer A, Roncari I, Garfmkel P. Effect of patient education on medication compliance. Can J Psychiatry 1980; 25: 638-645.
75. Kelly GR, Scott JE, Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990; 28: 1181-1197.
76. Boczkowski JA, Zeichner A, DeSanto N. Neuroleptic compliance among chronic schizophrenic outpatients. J Consult Clin Psychol 1985; 53:666-671.
77. Kelly GR, Mamon JA, Scott JE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc Sci Med 1987; 25: 1205-1211.
78. Marder SR, Mebane A, Chien C et al. Acomparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatr 1983; 140:470-472.
79. McEvoy JP, Fréter S, Everett G et al. Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis 1989; 177:48-51.
80. Meichenbaum D, Turk DC. Facilitating treatment adherence: a practitioner's guidebook,. New York: Plenum Press, 1987;
81. Corrigan PW, Liberman RP, Engel JD. From non-compliance to collaboration in the treatment of schizophrenia. Hospital and Community Psychiatry 1990; 41: 1203-1211.
82. Kemp R, Hay ward P, Applewhaite G et al. Compliance therapy in psychotic patients: randomised controlled trial. Br Med J 1996; 312: 345-349.
83. Rollnick S, Heather N, Bell A. Negotiating behaviour change in medical settings: the development of brief motivational interviewing. J Ment Health 1992; 1:25-37.
84. Davis JM. Overview: Maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatr 1975; 132: 1237-1245.
85. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. Br Med J 1971:3:599-604.
86. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9: 17-20.
87. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatr 1995; 40: S5-S11.
88. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatr 1984; 141: 748-752.
89. Teicher MH, Baldessarini RJ. Selection of neuroleptic dose. Arch Gen Psychiatr 1985; 42: 636-637.
90. Bollini P, Pampallona S, Orza MJ et al. Antipsychotic drugs: is more worse? A meta -analysis of the published randomized controlled trials. Psychol Med 1994; 24: 307-316.
91. Carpenter WT, Heinrichs DW. Early intervention and time-limited targeted pharmacotherapy of schizophrenia. Schizophrenia Bull 1983; 9: 533-535.
92. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophrenia Bull 1991; 17: 311-324.
93. Gaebel W. Is intermittent early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol 1995; 9:11 -16.
94. Marder SR, Van Putten T, Mintz J et al. Low and conventional-dose maintenance therapy with fluphenazine decanoate. Two year outcome. Arch Gen Psychiatry 1987: 44: 5 (8-521.
95. Birchwood M. Early intervention in schizophrenia: theoretical background and clinical strategies. Br .1 Clin Psychol 1992; 31: 257-278.
96. Subotnik KL, Nuechterlein KH. Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol 1988; 97: 405-412.
97. Hirsch SR, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psychiatr 1989; 155: 46-50.
98. Birchwood M, Smith J, Macmillan F et al. Predicting relpase in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers. Psychol Med 1989; 19: 649-656.
99. McCandless-GHncher L, McKnight S, Hamera E et al. Use of symptoms by schizophrenics to monitor and regulate their illness. Hasp Comm Psychiatr 1986; 37: 929-933.
100. Brown GW. Birley JLT, Wing JK. Influence of family life on the course of schizophrenia disorders: replication. Br J Psychiatr 1972:121: 241-258.
101. Kavanagh DJ. Recent developments in Expressed Emotion and schizophrenia. Br J Psychiatr 1992: 160: 601-620.
102. Bebbington P, Kuipers L. The clinical utility of expressed emotion in schizophrenia. Acta Psychiatr Scan (suppl.) 1994: 382: 46-53.
103. Jenkins JH, Karno M. The meaning of Expressed Emotion: theoretical issues raised by cross cultural research. Am J Psychol 1992; 149:9-21.
104. Falloon IRH, Boyd JL, McGill CW. Family Care of Schizophrenia. New York: Guilford Press, 1984.
105. Lam DH. Psychosocial family intervention in schizophrenia: a review of empirical studies. Psychol Med 1991; 21: 423-441.
106. Birchwood M, Tarrier N. introduction. In: Birchwood M, Tarrier N, Eds. Psychological Management of Schizophrenia, Chichester. Wiley, 1994.
107. Tarrier N, Barrowclough C, Vaughn C et al. The community management of schizophrenia: a controlled trial of behavioural intervention with families to reduce relapse. Br J Psychiatr 1988; 153: 532-542.
108. Curson DA, Patel M, Liddle PF et al. Psychiatric morbidity of a long stay hospital population with chronic schizophrenia and implications for future community care. Br Med J 1988; 297: 819-822.
109. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bull 1991; 17: 217-245.
110. Delva NJ. Letemendia FJ. Lithium treatment in schizophrenia and schizo-affective disorders. Br J Psychiatr 1982; 141: 387-400.
111. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: A review. J Psychiatr Neurosci 1992: 17: 1-14.
112. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am J Psychiatr 1991; 148: 714-726.
113. Wolkowitz OM, Turetsky N, Reus VI et al. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. PsychopharmacolBull 1992:28:291-295.
114. Bodkin JA. Emerging uses for high-potency benzodiazepines in psychotic disorders. J Clin Psychiatr 1990; 51: 41-46.
115. Bondolfi G, Baumann P, Patris M et al. A randomized double-bind trial of respiridone versus clozapine for treatment-resistant chronic schizophrenia (Abstract). Eur Neuropsychopharmacol 1995; 5: 349.
116. Klieser E, Lehmann E, Kinzler E et al. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15: 45S-51S.
117. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995; 15: 24S-29S.
118. Wetzel H, Szagedi A, Hain C et al. Seroquel (ICI 204 636), a putative 'atypical' antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEC parameters. Psychopharmacol Berl 1995; 119: 231-238.
119. Gunderson JG. Effects of psychotherapy in schizophrenia: II. Comparative outcome of two forms of treatment. Schizophrenia Bull 1984; 10: 564-598.
120. Tarrier N. Psychological treatment of positive schizophrenic symptoms. In: Kavanagh DJ, Eds. Schizophrenia: An Overview and Practical Handbook, London: Chapman and Hall, 1992: 357-373,
121. Hawton K, Salkovskis PM, Kirk J et al. Ed. Cognitive Behaviour Therapy for Psychiatric Problems: A Practical Guide. Oxford: Oxford University Press, 1989: 456.
122. Chadwick P, Löwe CF. The measurement and modification of delusional beliefs. J Consult Clinical Psychol 1990; 58: 225-232.
123. Garety PA, Kuipers L, Fowler D et al. Cognitive behavioural therapy for drug-resistant psychosis. Br J Med Psychol 1994; 67: 259-271.
124. Kingdon D, Turkington D, John C. Cognitive behaviour therapy of schizophrenia. Br J Psychiatr 1994; 164: 581-587.
125. Chadwick PD, Lowe CF. A cognitive approach to measuring and modifying delusions. Behav Res Ther 1994; 32: 355-367.
126. Tarrier N, Beckett R, Harwood S et al. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. Outcome. Br J Pswhiatr 1993: 162: 524532.
127. Bentall RP, Jackson HF, Pilgrim D. Abandoning the concept of 'schizophrenia': Some implications of validity arguments of psychological research into psychotic phenomena. Br J Clin Psychol 1988; 27: 303-324.
128. Bentall RP, Slade PD. Reality testing and auditory hallucinations: a signal detection analysis. Br J Clin Psychol 1985; 24: 159-169.
129. Huffman RE. The Duphar Lecture: On the etiology of alien, nonself attributes of schizophrenic "voices", Psychopathology 1991: 24: 347-355.
130. Fowler D, Morely S. The cognitive-behavioural treatment of hallucinations and delusions: a preliminary study. Behav Psychother 1989; 17: 267-282.
131. Chadwick PD, Birchwood MJ. The omnipotence of voices. A cognitive approach to auditory hallucinations. Br J Psychiatr 1994; 164: 190-201.
132. Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985; 11: 440-452.
133. Carpenter WTJ. The negative symptom challenge. Arch Gen Psychiatr 1992; 49: 236-237.
134. Kraeplin E. Lectures on Clinical Psyhiatry. Johnstone T, Ed. New York: Hafner, 1904.
135. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press, 1950, 1911.
136. Elliott R, Sahakian BJ. The neuropsychology of schizophrenia: relations with clinical and neurohiological dimensions. Psychol Mcd 1995; 25: 581-594.
137. Comblait B, Lenzenweger MF, Dworkin RH el al. Childhood attentional dysfunction predicts social deficits in unaffected adults at risk for schizophrenia. Br J Psychiatr 1992: 161 (suppl.18): 59-64.
138. Nuechterlein KH. Buchsbaum MS, Dawson ME. Neuropsychological Vulnerability to Schizophrenia. In: David AS, Cutting JC. Eds. The Neuropsychology of Schizophrenia, Hove (UK) Hillsdale (USA): Lawrence Erlbaum Associations, 1994: 53-77.
139. Kane JM, Mayerhoff D. Do negative symptoins respond to pharmacological treatment? Br J Psychiatr 1989; 155: 115-118.
140. Boyer P, Lecrubier Y, Puech AJ et al. Treatment of negative symptoms in schizophrenia with amisulpride. Brit J Psychiatry 1995; 166: 68-72.
141. Palliere-Martintot ML, Lecrubier Y, Martinot JL et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpiride. Am J Psychiatr 1995: 152: 130-133.
142. Miller DD, Perry PJ, Cadoret RJ et al. Clozapine's effects on negative symptoms in treatment-refractory schizophrenics. ComprP.ivchiatry 1994:35: X-15.
143. Lindenmayer JP. Grochowski S. Mabugat L. Clozapine's effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14: 201-204.
144. OplerLA. New agents for treating negative symptoms. New Anlipsychotic Treaiments for Schizophrenia Symposium ( 1994. Philadelphia, Pennsylvania). Psychiatr Ann 1995; 25: 301-305.
145. Chouinard G, Arnott W. Clinical review of risperidone. Can .1 Psyc/iiütr 1993; 38 (suppl. 3): S89-S95.
146. Davis KL, Kahn RS. Ko G el al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-1486.
147. Puech AJ. Rioux P. Poncelet M et al. Pharmacological properties of new antipsychotic agents: use of animal models. Neuropharmacology 1981; 20: 1279-1284.
148. Meltzer HY. The mechanism oi action of novel antipsychotic drugs. Schizophrenia Bull 1991; 17: 263-287.
149. Schmidt CJ. Sorensen SM. Kehne JH el al. The role of 5-HT2A receptors in antipsychotic aclivity. Life 1995; 56: 2209-2222.
150. Carpenter WTJ. Conley RR. Buchanan RW el al. Patienl response and resource management: another view of clo/apine treatment of schizophrenia. Am J Psychiatr 1995; 152: 827-832.
151. Moller HJ. Ncuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. European Nenropsychophcritiacol 1993: 3: 1-11.
152. Bracly JP. Social skills training for psychiatric patients. II: clinical outcome studies. Am J Psychiatry 1984; 141: 491-498.
153. Wirshing WC. Marder SR. Eckman Tel al. Acquision and retenlion of skills iraining methods in chronic schizophrenic outpatients. Psychopharmacol Bull 1992; 28: 241 -245.
154. Benton MK, Schroeder HE. Social skills training with schizophrenics: a meta-analytic evaluation. J Consult Clin Psychol 1990; 58: 741 -747.
155. Bellack AS. Saycrs M. Mueser KT et al. Evaluation of social problem solving in schizophrenia. J Abnorm Psychol 1994; 103:371-378.
156. Savers MD. A.S. B. Wade JH et al. An empirical method for assessing social problem solving in schizophrenia. Beliav Modif 1995; 19: 267-89.
157. Hansen DJ. Si Lawrence JS. Crisloff K A. Effects of interpersonal problem-solving iraining with chronic aftercare patients on problemsolving component skills and effectiveness of solutions../ Consult din Psycho/ 1985; 53: 167-174.
158. Holzman PS. Parsing cognition. The power of psychology paradigms. Arch Gen Psychiatr 1994; 51: 952-954.
159. Morice R. Cognitive inflexibility and prefromal dysfunction in schizophrenia and mania. Br J P.sychiatr 1990: 157: 50-54.
160. Buchanan RW. Holstein C. Brcier A. The comparative efficacy and long-term effect of clolapine treatment on neuropsychological lest performance. Bio/ Psychiatr 1994; 36: 717-725.
161. Hagger C. Buckley P. Kenny JT et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatr 1993: 34: 702-712.
162. Lee MA, Thompson PA. Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatr 1994:55 (suppl.B): 82-87.
163. Green MF. Cognitive remediation in schizophrenia: is it time yet? Am J Psychiatr 1993: 150: 178-187.
164. Gross Y, Schutz LE. Intervention models in neuropsychology. In: U/zell BP, Gross Y. Eds. Clinical Neum/ysycholoiy of Intervention, Boston: Martinus NijhotT. 1986.
165. Luria AR, Naydin V. Tsevetkova IS et al. Restoration of higher cortical function following local brain damage. In: Yinken R, Bryn G. Eds. Handbook of Clinical Neurology. Amsterdam, North Holland: 1969.
166. Wallace CJ. Liberman RP. Social skills training for pateints with schizophrenia: A controlled clinical trial. Psychiatr Res 1985; 15: 239-247.
167. Velligan Dl, True JE, LeftonRS et al. Cognitive adaptation training: compensatory strategies in psychosocial intervention with schizophrenic patients (Abstract). Schizophrenia Res 1995; 15: 222.
168. Goldberg TE. Weinberger DR. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophrenia Hull 1988; 14: 179-183.
169. Green MF, Satz P. Ganzell S et al. Wisconsin Card Sorting Test Performance in schizophrenia: remediation of a stubborn deficit. Am J Psyr/iiair 1992; 149:62-67.
170. Summerfell AT, Alphs LD. Wagman AM. Reduction in perseverative errors in patients with schizophrenia using monetary feedback. J Ahnorm Psychol 1991: 100: 613-616.
171. Lindstrom LH. A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychophanmicology 1989; 99: 92-96.
172. Meltzer HY. Multiple-outcome criteria in schizophrenia: An overview of outcome with clozapine. European Psychiatry 1995: lOlsuppl. 1): I9S-25S.
173. Meltzer HY. Burnett S. Bastani B et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Coiiuii Pxycliintr 1990: -41: 892-897.
174. Liberman RP, Spaulding WD, Corrigan PW. Cognitive behavioural therapies in psychiatric rehabilitation. In: Hirsch SR, Wcinberger DR. Eds. Sihizophrenia. Oxford: Blackwell Science, 1995: 605-625."
175. MIND. Commun Concern. London: MIND. 1983.
176. National Institute of Mental Health. Towards a model plan for u comprehensive community-based menial health system. NIMH. US Department of Health and Human Services. 1987.
177. David A. On the street in America. BrMedJ 1988; 296: 1016.
178. Her Majesty's Stationery Office. Caring for People. London: HMSO. 1989."
179. Her Majesty's Stationery Office. Working for patients. London: HMSO, 1989.
180. Intagliata J. Improving the quality of care for the chronically mentally disabled: the role of case management. Schizophrenia Bull 1982:8: 655-674.
181. Kanter J. Clinical case management: definition, principles, components. Hosp Connu Psyi Itiutr 1989; 40: 361-368.
182. NHS Management Executive. Introduction of supervision registers for mentallv iU people from I April 1994. Leeds: NHSME. 1994. (HSG(94)27.)
183. Holloway F, McClean E. Robertson JA. Case Management, Br./ Psychiatr 199L 159: 142-148.
184. Rapp CA. Wintersteen R. The strengths model of case management: results from 12 demonstrations. Psychosoc RehabilJ 1989: 13: 23-32.
185. Muijen M. The balance of care. In: Birchwood MJ. Tarrier N. Eds. Innovations in the Psychological Management nf Schizophrenia. Chichester: John Wiley & Sons. 1992: 253-275.
186. Lehman AF. Strategies for improving services for the chronically mentally ill. Hosp Comm Psychiatr 1989: 40: 916-920.
187. Holloway F. Oliver N. Collins E et al. Case management: a critical review of the outcome literature. Enr Psychiatr 1995: 10: 113-128.
188. Kura.su T. Psychotherapy and pharmacotherapy: Towards an integrative model.,ni.lPsy Itiatr 1982; 139: 1102-1113"
189. Hogarty GE. Prevention of relapse in chronic schizophrenic patients. J Clin Psyc'hialr 1993:54: 18-23.
190. Van Putten T. Marshall BD. Liherman R et al. Systematic dosage reduction in treatment-resistant schizophrenic patients. Psychopharmacol Bull 1993:29: 315-320.